Gries Financial LLC Has $2.52 Million Stake in Becton, Dickinson and Company $BDX

by · The Markets Daily

Gries Financial LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 75.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,484 shares of the medical instruments supplier’s stock after purchasing an additional 5,818 shares during the period. Gries Financial LLC’s holdings in Becton, Dickinson and Company were worth $2,524,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. RiverGlades Family Offices LLC bought a new position in Becton, Dickinson and Company during the second quarter worth $344,000. Covea Finance grew its holdings in Becton, Dickinson and Company by 10.7% in the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock worth $14,758,000 after purchasing an additional 7,610 shares during the period. B. Riley Wealth Advisors Inc. bought a new stake in Becton, Dickinson and Company in the second quarter valued at $983,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in shares of Becton, Dickinson and Company by 2.0% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 905,757 shares of the medical instruments supplier’s stock worth $169,531,000 after purchasing an additional 17,844 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the transaction, the executive vice president owned 13,105 shares of the company’s stock, valued at $2,568,973.15. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,052 shares of company stock valued at $201,235 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on BDX shares. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Jefferies Financial Group increased their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Argus upped their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Bank of America lifted their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $207.18.

View Our Latest Stock Report on BDX

Becton, Dickinson and Company Trading Up 2.0%

NYSE:BDX opened at $198.91 on Tuesday. The stock has a market cap of $56.67 billion, a price-to-earnings ratio of 34.12, a PEG ratio of 1.80 and a beta of 0.23. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company’s 50 day moving average price is $191.27 and its 200-day moving average price is $187.41.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Featured Stories